Tag: PD-L1 Inhibitors

Home / PD-L1 Inhibitors

Categories

Cosibelimab-ipdl is approved by the USFDA for metastatic or locally advanced cutaneous squamous cell carcinoma

 On December 13, 2024, the Food and Drug Administration sanctioned cosibelimab-ipdl (Unloxcyt, Checkpoint Therapeutics, Inc.), a programmed death ligand-1 (PD-L1) inhibiting antibody, for adults with...
pd-l1-inhibitors

Scan the code